I Want To...
I Want To...
Find Research Faculty
Enter the last name, specialty or keyword for your search below.
School of Medicine
I Want to...
Sandra Beatriz Gabelli, Ph.D.
Associate Professor of Medicine
Research Interests: Nudix hydrolases; Isoprenoid pathway as a target of protozoan parasitic diseases; PI3K/mTOR pathways
Dr. Sandra Gabelli is an Assistant Professor of Medicine in the Biophysics and Biophysical Chemistry and Oncology departments. She studies the molecular mechanisms of signal transduction and oncogenic activation in the PI3K/mTOR pathways. She is also studying the isoprenoid pathway as a target of protozoan parasitic diseases.
Dr. Gabelli holds a Ph.D. from Johns Hopkins University and completed postdoctoral research at Johns Hopkins before joining the faculty. She is a member of the Johns Hopkins Kimmel Cancer Center.
- Associate Professor of Medicine
- Assistant Professor of Art as Applied to Medicine
- Associate Professor of Biophysics and Biophysical Chemistry
- Associate Professor of Oncology
Departments / Divisions
Centers & Institutes
- Licenciatura, Universidad Nacional Del Sur (Argentina) (1988)
- Ph.D., Johns Hopkins University School of Medicine (Maryland) (2000)
Research & Publications
Dr. Gabelli's research is focused on understanding the molecular mechanisms of signal transduction and oncogenic activation in the PI3K/mTOR pathways. She is also studying the isoprenoid pathway as a target of protozoan parasitic diseases.
Lab Website: Sandra Gabelli Laboratory
Technology Expertise Keywordsstructural biology, drug discovery, X-ray crystallography, SAXS, protein expression and purification
Selected PublicationsView all on Pubmed
Boto AN, Xu W, Jakoncic J, Pannuri A, Romeo T, Bessman MJ, Gabelli SB, Amzel LM. Structural studies of the Nudix GDP-mannose hydrolase from E. coli reveals a new motif for mannose recognition. Proteins. 2011 Aug;79(8):2455-66.
Duong-Ly KC, Gabelli SB, Xu W, Dunn CA, Schoeffield AJ, Bessman MJ, Amzel LM. The Nudix hydrolase CDP-Chase, a CDP-choline pyrophosphatase, is an asymmetric dimer with two distinct enzymatic activities. J Bacteriol. 2011 Jul;193(13):3175-85.
Gabelli SB, Duong-Ly K, Brower ET, Amzel LM . Capitalizing on tumor genotyping: Towards the design of mutation specific inhibitors of phosphoinsitide-3-kinase. Adv Enzyme Regul. 2011;51(1):273-9.
Messing SAJ, Gabelli SB, Echeverria I, Vogel JT, Guan JC, Tan BC, Klee HJ, McCarty DR, Amzel LM. Structural Insights into Maize Viviparous14, a Key Enzyme in the Biosynthesis of the Phytohormone Abscisic Acid. Plant Cell. Sep;22(9):2970-80.
Schmidt-Kittler O, Zhu JX, Yang J, Liu G, Hendricks W, Lengauer C, Gabelli SB, Kinzler KW, Vogelstein B, Huso DL, Zhou S. PI3Kα Inhibitors That Inhibit Metastasis. Oncotarget. 2010 Sep;1(5):339-48.
Mohan S, Tse CM, Gabelli SB, Sarker R, Cha B, Fahie K, Nadella M, Zachos NC, Tu-Sekine B, Raben D, Amzel LM, Donowitz M. NHE3 activity is dependent on direct phosphoinositide binding at the N-terminus of its intracellular cytosolic region. J Biol Chem. 2010 Nov 5;285(45):34566-78.
Gabelli SB, Huang CH, Mandelker D, Schmidt-Kittler O, Vogelstein B, Amzel LM Structural Effects of Oncogenic PI3Kalpha Mutations. Curr Top Microbiol Immunol. 2010;347:43-53
Barrila J, Gabelli SB, Bacha U, Amzel LM, Freire E. Mutation of Asn28 disrupts the dimerization and enzymatic activity of SARS 3CL(pro). Biochemistry. 2010 May 25;49(20):4308-17.
Gabelli SB, Mandelker D, Schmidt-Kittler O, Vogelstein B, Amzel LM. Somatic mutations in PI3Kalpha: Structural basis for enzyme activation and drug design. Biochim Biophys Acta. 2010 Mar;1804(3):533-40.
Huang CH, Gabelli SB, Oldfield E, Amzel LM. Binding of nitrogen-containing bisphosphonates (N-BPs) to the Trypanosoma cruzi farnesyl diphosphate synthase homodimer Proteins. Proteins. 2010 Mar;78(4):888-99.
Videos & Media
Recent News Articles and Media Coverage
Sandra Gabelli on Protein Structures and Pasta (Fundamentals)